Kidney Cancer Weekly

October 27, 2025

Videos

Peer-to-Peer Clinical Conversations

Diagnostic Imaging and Treatment Options for Small Renal Masses - Fernando Pablo Secin

Fernando Secin

Zachary Klaassen hosts Fernando Secin to discuss the management of small renal masses.

Identifying the Right Patient for [⁸⁹Zr]Zr-Girentuximab PET–CT Imaging in Clear Cell RCC - Vitaly Margulis

Joseph Prijdekker

Zachary Klaassen and Vitaly Margulis explore the emerging role of Girentuximab PET-CT in kidney cancer management.

Beyond the Abstracts

Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis - Beyond the Abstract

Clinical Applications of Microbiome in Renal Cell Carcinoma - Beyond the Abstract

Conference Coverage

ESMO 2025: [68Ga]Ga-DPI-4452 PET/CT for Staging of Patients with Clear Cell Renal Cell Carcinoma

ESMO 2025: Identifying Biomarkers of Response to First-Line Nivolumab plus Ipilimumab Therapy in Patients with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC) enrolled in the COSMIC 313 trial

ESMO 2025: Lymphocyte Activation Gene-3 (LAG3) Expression Patterns and Immunotherapy (IO) Response in Metastatic Renal Cell Carcinoma (mRCC)

ESMO 2025: Exploratory Analysis of Chromophobe Renal Cell Carcinoma in the SUNNIFORECAST Trial Comparing Ipilimumab plus Nivolumab vs Standard of Care as First Line Treatment

ESMO 2025: Genomic Analysis of Papillary Renal Cell Carcinoma (PRCC): MET Alterations Are Uncommon and Enriched in Patients of African Ancestry

Articles

Editor Selected Abstracts and Commentaries

Renal Cancer

A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo).

Management of Renal Cell Carcinoma of Variant Histology.

Novel pembrolizumab-based treatments as first-line therapy in advanced clear cell renal cell carcinoma: Substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial.

Comparison of health economics in robot-assisted partial nephrectomy and CT-guided cryoablation for the management of T1 renal cell carcinoma: an analysis of a prospective Danish cohort.

Updated 2025 French Guidelines for Renal Cell Carcinoma.

FAP Expression in Renal Tumors Assessed by [68Ga]Ga-FAPI-46 PET Imaging and FAP Immunohistochemistry: A Case Series of Six Patients from the Prospective Exploratory Trial NCT04147494.

Cambridge kidney One-Stop Mass Investigation Clinic (CkOSMIC): A Nonrandomised Feasibility Study.

Local Recurrence After Nephron Surgery: What to Do? An Italian Multicentric Registry.

A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions.

CABOSEQ 3-Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium

Real World Efficacy of 1st-Line Nivolumab Plus Ipilimumab and its Practical Predictive Biomarkers in Advanced Renal Cell Carcinoma: First Analysis from RENOIR Study (KCSG GU22-13).

End-of-Life and Palliative Care in Patients with Metastatic Renal Cancer - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC